Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a…



















